Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Is Viking Therapeutics Stock a No-Brainer Buy Below $35?
12:30am, Tuesday, 23'rd Jun 2026
Viking Therapeutics is running phase 3 studies for its leading anti-obesity candidate. Its shares could soar from current levels, provided everything goes according to plan.
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
08:15pm, Monday, 22'nd Jun 2026
Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinica
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
06:50pm, Wednesday, 17'th Jun 2026
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $30.29, indicating a +2.16% shift from the previous trading day.
Is Viking Therapeutics Stock Going to $100?
01:15am, Friday, 12'th Jun 2026
Viking is developing candidates in the high-growth weight loss drug market. The company's lead candidate is involved in late-stage studies.
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.
07:05am, Thursday, 11'th Jun 2026
Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
06:50pm, Wednesday, 10'th Jun 2026
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
01:27pm, Wednesday, 10'th Jun 2026
The global market for drugs that treat obesity could be worth $150 billion by 2035. Viking Therapeutics is developing a pill and an injectable version of its weight-loss candidate.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
06:45pm, Thursday, 04'th Jun 2026
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
03:32pm, Thursday, 04'th Jun 2026
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
06:49am, Wednesday, 03'rd Jun 2026
Eli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market. Investors are hoping Viking's VK2735 will prove efficacious and safe in its Phase 3 clinical
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
10:48am, Tuesday, 02'nd Jun 2026
An upcoming trial result could change how investors think about the weight-loss drug market.
The Smartest Growth Stocks to Buy With $2,000 Right Now
06:15am, Saturday, 30'th May 2026
Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
12:31pm, Friday, 29'th May 2026
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
06:46pm, Thursday, 28'th May 2026
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.
